A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection

• ClinicalTrials.gov Identifier: NCT01588249
• Recruitment Status: Terminated
• First Posted: April 30, 2012
• Last Update Posted: October 11, 2012
• Sponsor: Zarbee's Inc.
• Collaborator: Advanced Clinical Research
• Information provided by (Responsible Party): Zarbee's Inc.

Study Description

Brief Summary:

Cough is a frequent symptom in children and infants and is one of the most common reasons parents visit a healthcare provider for their child. The US Food and Drug Administration has issued a warning that over-the-counter cough and cold medicines including antihistamines, decongestants, anti-tussives, and expectorants should not be administered to children younger than 2 years of age due not only to lack of proven efficacy, but also because of important safety concerns. A product that has been used in alternative medicine for cough is maple syrup. Although no studies have formally evaluated the use of maple syrup for nocturnal cough associated with URI, the demulcent effect of maple syrup may provide some relief from cough in children. A novel formulation of pasteurized maple cough syrup, when compared to placebo, should provide superior relief on nocturnal cough and the sleep difficulty associated with URI in children under 12 months and sleep difficulty of their parent/caregiver.

Condition or disease	Intervention/treatment	Phase
Cough; Upper Respiratory Infection; Nocturnal Cough	Dietary Supplement: Pasteurized maple syrup; Dietary Supplement: Placebo	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 80 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection
• Study Start Date: April 2012
• Actual Primary Completion Date: June 2012
• Actual Study Completion Date: June 2012

Arms and Interventions

Arm	Intervention/treatment
Experimental: Novel formulation of pasteurized maple cough syrup	Dietary Supplement: Pasteurized maple syrup
Placebo Comparator: Placebo	Dietary Supplement: Placebo

Outcome Measures

Primary Outcome Measures :

1. Change from baseline in cough frequency between the first night and the end of the second night. [ Time Frame: baseline and day 2 ]

Eligibility Criteria

• Ages Eligible for Study: up to 12 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

1. Otherwise healthy male or female infant who is between 0 and 12 months of age.
2. Presents to clinic with a URI characterized by the presence of rhinorrhea and cough for 7 or fewer days' duration.
3. Patient is an appropriate candidate, in the judgment of the investigator, to participate in the study.
4. Parents/caregivers provide an answer of at least "somewhat" (3 points on a 7-point Likert scale) for a minimum of 2 of the 3 questions related to nocturnal cough frequency, effect on child's sleep, and effect on parental/caregiver sleep based on the previous night's symptoms (see Section 11.0).
5. Parent/legal authorized representative provides written informed consent for child to participate in study.
6. Parent/caregiver who is willing and able to comply with study requirements.

Exclusion Criteria

1. Signs or symptoms of a more treatable disease (eg, asthma, pneumonia, laryngotrachebronchitis, sinusitis, allergic rhinitis).
2. Diagnosis of influenza, bronchiolitis or respiratory syncytial virus (RSV).
3. History of reactive airways disease, asthma, or chronic lung disease.
4. Use of any medication to treat cough within 6 hours of bedtime on the evening prior to or on the day of enrollment. (Use of analgesic medications such as acetaminophen or ibuprofen is not exclusionary.)
5. Presence of any significant disease including immunodeficiency, hepatic, renal, cardiovascular, or hematologic disease or any other health condition that, in the opinion of the investigator, would preclude participation in the study.

Contacts and Locations

Locations

United States, Utah

Willow Creek Pediatrics

Draper, Utah, United States

Families First Pediatrics

South Jordan, Utah, United States

Southwest Children's Clinic

West Jordan, Utah, United States

Sponsors and Collaborators

Zarbee's Inc.

Advanced Clinical Research

More Information

• Responsible Party: Zarbee's Inc.
• ClinicalTrials.gov Identifier: NCT01588249
• Other Study ID Numbers: ZMCS-6441
• First Posted: April 30, 2012
• Last Update Posted: October 11, 2012
• Last Verified: October 2012

Additional relevant MeSH terms:

Infections; Communicable Diseases; Respiratory Tract Infections; Cough; Disease Attributes; Pathologic Processes; Respiration Disorders; Respiratory Tract Diseases; Signs and Symptoms, Respiratory